News
ZYXI
11.23
-0.27%
-0.03
Weekly Report: what happened at ZYXI last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ZYXI last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at ZYXI last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at ZYXI last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at ZYXI last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at ZYXI last week (0311-0315)?
Weekly Report · 03/18 09:11
Zynex Full Year 2023 Earnings: Misses Expectations
Zynex missed analyst estimates by 3.8%. The company's share price is broadly unchanged from a week ago. Electrotherapy and Pain Management Products contributed US$184.3m in the last 12 months. Revenue is forecast to grow 19% p.a. On average during the next 3 years.
Simply Wall St · 03/14 10:20
Zynex Inc. at a Crossroads: $60 Million Convertible Notes Pose Liquidity and Dilution Risks
TipRanks · 03/14 06:02
Weekly Report: what happened at ZYXI last week (0304-0308)?
Weekly Report · 03/11 09:11
Zynex (ZYXI) Receives a Buy from RBC Capital
TipRanks · 03/08 12:27
Weekly Report: what happened at ZYXI last week (0226-0301)?
Weekly Report · 03/04 09:11
Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Zynex, Inc. Released its full-year results last week. The company fell short of expectations and statutory earnings missed forecasts by 33%. The analysts are now downgrading their revenue estimates for next year. However, the consensus price target for the company has risen 17% to US$18.98. Zynex's revenue growth is expected to slow but is still expected to grow faster than the industry.
Simply Wall St · 03/03 13:55
Zynex Price Target Raised to $15.00/Share From $13.00 by RBC Capital
Dow Jones · 03/01 16:02
Zynex Is Maintained at Outperform by RBC Capital
Dow Jones · 03/01 16:02
RBC Capital Maintains Outperform on Zynex, Raises Price Target to $15
Benzinga · 03/01 15:52
RBC Capital Remains a Buy on Zynex (ZYXI)
TipRanks · 03/01 12:27
Zynex Price Target Raised to $21.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 03/01 12:19
Zynex Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/01 12:19
HC Wainwright & Co. Maintains Buy on Zynex, Raises Price Target to $21
Benzinga · 03/01 12:09
Buy Rating Affirmed for Zynex on Strong Growth Prospects and Financial Health
TipRanks · 03/01 11:27
More
Webull provides a variety of real-time ZYXI stock news. You can receive the latest news about Zynex Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZYXI
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Company’s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.